Investment Rating - The investment rating for the company is "Buy" [5] Core Views - The company reported a revenue of 362 million yuan for 2025, representing a year-on-year increase of approximately 16.63%. The net profit attributable to the parent company reached 42.12 million yuan, showing a significant year-on-year growth of 222.20% [2][3] - The company is experiencing growth in revenue from sectors such as new materials, new energy, and pharmaceuticals, driven by a recovery in industry demand and advancements in high-end instrument manufacturing [3] - The company has maintained stable investments in product research and development, market expansion, and brand enhancement, leading to the introduction of advanced instruments like organic element analyzers and liquid chromatography instruments [3] Financial Summary - For 2025, the company expects net profit attributable to the parent company to be 42 million yuan, with an EPS of 0.49 yuan per share, corresponding to a PE ratio of 49.5 times [2][6] - The projected revenue and net profit for 2026 and 2027 are 434 million yuan and 53 million yuan, and 499 million yuan and 64 million yuan, respectively, indicating a consistent growth trajectory [6] - The gross margin is expected to remain stable around 64.8% to 65.1% over the next few years, while the net margin is projected to improve from 10.1% in 2025 to 12.4% in 2027 [6][7]
海能技术：新材料、新能源、制药等领域收入增长，2025年归母净利润同比+222%-北交-20260303